 Analysis of 30- and 90-day status will entail an informal comparison for the purposes of providing preliminary evidence and for planning of a larger comparative trial. The proportion of patients under experimental treatment who suffer from death or dependency at 30-days, as determined by cutoffs on the modified Rankin Scale with exact binomial upper and lower 90 confidence limits will be used in a comparison to our criteria of: 1 65 historical proportion of patients under medical management, unselected for baseline risk, and 2 50 proportion of patients under other minimally invasive surgical techniques unselected for baseline risk. This confidence limit comparative approach provides a flexible method of assessment of non-inferiority, equivalence, and superiority. The unselected population will, however, be a mix of patients at different levels of baseline risk, and so a follow-up stratified analysis will be conducted if counts permit. The unselected population will be matched using demographics, lesion characteristics and comorbidities as close as possible to the study group. A heterogeneity index will be used for comparison. As a corollary to this analysis, baseline predictive scores translated from scores to percentagesrisks will be used to calculate expected counts of 30 and 90 day status stratified within the 0-3 range of the Hemphill ICH score and 0-10 range of the Essen ICH score, and these expected counts will be compared to observed counts using a Fisher Exact Test. 